Lorus Therapeutics
Focused – Innovative – Effective: We are Lorus
  • Home
  • About Lorus
    • Overview
    • Message from the CEO
    • Management Team
    • Board of Directors
  • Products & Technology
    • Product Pipeline
    • Virulizin
    • LOR-2040
    • LOR-1284
    • LOR-253, LOR-264 and LOR-220
    • IL-17E
  • Investors
    • Overview
    • Financial Reports
    • Corporate Documents
    • Stock Information
    • Conference Calls & Webcasts
    • Corporate Governance
    • FAQ
    • Investors Contact & Information Request
  • News & Events
    • Press Releases
    • French Press Releases
    • Events
    • Subscription
  • Business Development
  • Contact
  • Careers
  • Subscription
  • Site Map

Investors

  • Overview
  • Financial Reports
  • Corporate Documents
  • Stock Information
  • Conference Calls & Webcasts
  • Corporate Governance
  • FAQ
  • Investors Contact & Information Request
  • Fact SheetFact Sheet
  • Corporate PresentationCorporate Presentation

Corporate Documents

  • Material Change Report - May 31, 2010 (PDF: 83 Kb)
  • Material Change Report - April 23, 2010 (PDF: 184 Kb)
  • Material Change Report - April 15, 2010 (PDF: 273 Kb)
  • Material Change Report - March 12, 2010 (PDF: 75 Kb)
  • Material Change Report - November 30, 2009 (PDF: 82 Kb)
  • Material Change Report - October 15, 2009 (PDF: 79 Kb)
  • Material Change Report - July 2, 2009 (PDF: 275 Kb)
 
© 2005-2010 Lorus Therapeutics Inc.  |  Legal Notice